EHMT2 and colorectal carcinoma: As for previous studies using the same class of small molecule inhibitors (dual G9a/GLP inhibitors) [17–20], we generalized our findings to G9a functions, since (1) knockdown experiments recapitulated chemical treatments and (2) no impact on RFS was observed for GLP overexpression in CRC patients.